SCHEMBL979771

SCHEMBL979771

CCC1=CC(=O)OC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18845026 0.82
SCHEMBL979693 0.79
SCHEMBL420617 0.76
SCHEMBL7338073 0.76
SCHEMBL419742 0.76
SCHEMBL9422903 0.76 HIF1A (0.43)
SCHEMBL7303716 0.76 HIF1A (0.43)
SCHEMBL18196023 0.72 ALDH1A1 (0.39)
SCHEMBL9423576 0.71
SCHEMBL981029 0.70 CALM1 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002436-A1 MODIFIED NUCLEOTIDES AND USES THEREOF FIRST-CITIZENS BANK & TRUST COMPANY 2023-01-05 US disclosed
US-11174281-B1 Modified nucleotides and uses thereof Singular Genomics Systems, Inc. (US) 2021-11-16 US disclosed
WO-2017011418-A1 ORGANIC REACTION UTILIZING AN α,β-UNSATURATED COMPOUND ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2017-01-19 WO disclosed
US-9364554-B2 Extracellular targeted drug conjugates CENTROSE LLC (US) 2016-06-14 US disclosed
US-8703723-B2 Glycoside compounds and pharmaceutical compositions thereof CENTROSE, LLC (US) 2014-04-22 US disclosed
US-8470980-B2 Extracellular targeted drug conjugates CENTROSE, LLC (US) 2013-06-25 US disclosed
US-8361973-B2 Glycoside compounds and pharmaceutical compositions thereof CENTROSE, LLC (US) 2013-01-29 US disclosed
WO-2012139891-A1 SUBSTITUTED VINYL AND ALKINYL CYCLOHEXENOLS AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS BAYER CROPSCIENCE AG (DE) 2012-10-18 WO disclosed
US-20110319350-A1 GLYCOSIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF CENTROSE, LLC (US) 2011-12-29 US disclosed
US-20110064752-A1 EXTRACELLULAR TARGETED DRUG CONJUGATES CENTROSE, LLC (US) 2011-03-17 US disclosed
US-20110014504-A1 LITHIUM SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2011-01-20 US disclosed
US-7619101-B2 Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one useful in the preparation of the DPP-IV inhibitor (S)-1 ((2S,3S,11bS)-2-amino-9,10-dimethoxy-1,3,4,6,7, 11b-hexahydro-2H-pyrido[2,1-a] isoquinolin-3-yl)-4-fluoromethyl-pyrrolidin-2-one HOFFMAN-LA ROCHE INC. (US) 2009-11-17 US disclosed
US-20080311478-A1 Lithium Secondary Battery MITSUBISHI CHEMICAL CORPORATION (JP) 2008-12-18 US disclosed
EP-1892789-A1 LITHIUM SECONDARY BATTERY Mitsubishi Chemical Corporation (JP) 2008-02-27 EP disclosed
US-20060270853-A1 Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one useful in the preparation of the DPP-IV inhibitor (S)-1 ((2S,3S,11bS)-2-amino-9,10-dimethoxy-1,3,4,6,7, 11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-3-yl)-4-fluoromethyl-pyrrolidin-2-one HOFFMANN-LA ROCHE INC. 2006-11-30 US disclosed
EP-0293748-B1 PROCESS FOR THE PREPARATION OF 2(5H)-FURANONES BASF Aktiengesellschaft (DE) 1992-01-29 EP disclosed
US-4853473-A Preparation of 2(5H)-furanones BASF AKTIENGESELLSCHAFT (DE) 1989-08-01 US disclosed
EP-0293748-A2 Process for the preparation of 2(5H)-furanones BASF Aktiengesellschaft (DE) 1988-12-07 EP disclosed